TOR-INHIBITORS (SIROLIMUS AND EVEROLIMUS) FOR PRIMARY IMMUNOSUPPRESSION OF RENAL TRANSPLANT RECIPIENTS: A META-ANALYSIS RANDOMISED TRIALS.